Pfizer's Xeljanz Gains FDA Panel Nod In Psoriatic Arthritis, But Labeling Questions Remain

 
• By Derrick Gingery
  
FDA entrance sign 2016

More from US FDA Performance Tracker

More from Regulatory Trackers